Oncogenesis and mutagenesis of pituitary tumors

Expert Review of Anticancer Therapy

Volumn 6, Issue 9 SUPPL., 2006, Pages

  Sonabend, Adam M ^a   Musleh, Wael ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adenoma; Biology; Chromosome; Genetics; Hypophysis; Oncogene; Pathophysiology; Pituitary; Syndrome; Tumor suppressor gene

Indexed keywords

ADENYLATE CYCLASE; AMINO ACID; ARGININE; CORTICOTROPIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; CYCLIN E; DOPAMINE 2 RECEPTOR; GROWTH HORMONE; METHIONINE; MYC PROTEIN; ONCOPROTEIN; PITUITARY TUMOR TRANSFORMING PROTEIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P16; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR PIT 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACROMEGALY; ALBRIGHT SYNDROME; AMINO ACID SUBSTITUTION; CARCINOGENESIS; CARNEY COMPLEX; CELL CYCLE REGULATION; CELL DISRUPTION; CELL POPULATION; CHROMOSOME 10; CHROMOSOME 11; CHROMOSOME 11Q; CHROMOSOME 13; CHROMOSOME DELETION; CORTICOTROPIN RELEASE; DISEASE ASSOCIATION; DRUG RESEARCH; DRUG TARGETING; GENE DISRUPTION; GENETIC PREDISPOSITION; GROWTH HORMONE RELEASE; HETEROZYGOSITY LOSS; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MOUSE; MULTIPLE ENDOCRINE NEOPLASIA; MUTAGENESIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANIMALS; GENE THERAPY; HUMANS; MUTAGENESIS; ONCOGENES; PITUITARY NEOPLASMS;

EID: 33750058242     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.9.S3     Document Type: Review

References (142)

1. Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N. Engl. J. Med. 304(3), 156-158 (1981).
2. Molitch ME, Russell EJ. The pituitary "incidentaloma". Ann. Intern. Med. 112(12), 925-931 (1990).
3. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr. Relat. Cancer 8(4), 287-305 (2001).
4. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers. occult adenomas in the general population. Ann. Intern. Med. 120(10), 817-820 (1994).
5. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr. Rev. 19(6), 798-827 (1998).
6. Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A, Klibanski A. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J. Clin. Invest. 86(1), 336-340 (1990).
7. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 71(6), 1427-1433 (1990).
8. Jacoby LB, Hedley-Whyte ET, Pulaski K, Seizinger BR, Martuza RL. Clonal origin of pituitary adenomas. J. Neurosurg. 73(5), 731-735 (1990).
9. Frohman LA, Kineman RD. Growth hormone-releasing hormone and pituitary somatotroph proliferation. Minerva Endocrinol. 27(4), 277-285 (2002).
10. Frohman LA, Kineman RD. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends Endocrinol. Metab. 13(7), 299-303 (2002).
11. Mayo KE, Hammer RE, Swanson LW, Brinster RL, Rosenfeld MG, Evans RM. Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol. Endocrinol. 2(7), 606-612 (1988).
12. Thorner MO, Perryman RL, Cronin MJ et al. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J. Clin. Invest. 70(5), 965-977 (1982).
13. Saeger W, Puchner MJ, Ludecke DK. Combined sellar gangliocytoma and pituitary adenoma in acromegaly or Cushing's disease. A report of 3 cases. Virchows Arch. 425(1), 93-99 (1994).
14. Puchner MJ, Ludecke DK, Valdueza JM et al. Cushing's disease in a child caused by a corticotropin-releasing hormone-secreting intrasellar gangliocytoma associated with an adrenocorticotropic hormone-secreting pituitary adenoma. Neurosurgery 33(5), 920-924; discussion 924-925 (1993).
15. de Keyzer Y, Rene P, Beldjord C, Lenne F, Bertagna X. Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clin. Endocrinol. (Oxf) 49(4), 475-482 (1998).
16. de Keyzer Y, Rene P, Lenne F, Auzan C, Clauser E, Bertagna X. V3 vasopressin receptor and corticotropic phenotype in pituitary and nonpituitary tumors. Horm. Res. 47(4-6), 259-262 (1997).
17. de Keyzer Y, Lenne F, Auzan C et al. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J. Clin. Invest. 97(5), 1311-1318 (1996).
18. Kaji H, Xu Y, Takahashi Y, Abe H, Tamaki N, Chihara K. Human TRH receptor messenger ribonucleic acid levels in normal and adenomatous pituitary. analysis by the competitive reverse transcription polymerase chain reaction method. Clin. Endocrinol. (Oxf.) 42(3), 243-248 (1995).
19. Chen L, Puri R, Lefkowitz EJ, Kakar SS. Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization. Gene 248(1-2), 41-50 (2000).
20. Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J. Biol. Chem. 275(11), 7459-7461 (2000).
21. Trautmann K, Thakker RV, Ellison DW et al. Chromosomal aberrations in sporadic pituitary tumors. Int. J. Cancer 91(6), 809-814 (2001).
22. Metzger AK, Mohapatra G, Minn YA et al. Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization. J. Neurosurg. 90(2), 306-314 (1999).
23. Hentschel SJ, McCutcheon E, Moore W, Durity FA. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can. J. Neurol. Sci. 30(3), 215-219 (2003).
24. Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa-Coutinho LM, Ferreira NP. Expression of p53 protein in pituitary adenomas. Braz. J. Med. Biol. Res. 35(5), 561-565 (2002).
25. Cai WY, Alexander JM, Hedley-Whyte ET et al. ras mutations in human prolactinomas and pituitary carcinomas. J. Clin. Endocrinol. Metab. 78(1), 89-93 (1994).
26. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL. Ras mutations in human pituitary tumors. J. Clin. Endocrinol. Metab. 74(4), 914-919 (1992).
27. Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D. H-ras mutations in human pituitary carcinoma metastases. J. Clin. Endocrinol. Metab. 78(4), 842-846 (1994).
28. Lania A, Mantovani G, Spada A. Genetics of pituitary tumors: focus on G-protein mutations. Exp. Biol. Med. (Maywood) 228(9), 1004-1017 (2003).
29. Woloschak M, Roberts JL, Post K. c-myc, c-fos, and c-myb gene expression in human pituitary adenomas. J. Clin. Endocrinol. Metab. 79(1), 253-257 (1994).
30. Zhang X, Horwitz GA, Heaney AP et alal. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 84(2), 761-767 (1999).
31. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur. J. Endocrinol. 143(1), R1-R6 (2000).
32. Clementi E, Malgaretti N, Meldolesi J, Taramelli R. A new constitutively activating mutation of the Gs protein α subunit-gsp oncogene is found in human pituitary tumours. Oncogene 5(7), 1059-1061 (1990).
33. Williamson EA, Daniels M, Foster S, Kelly WF, Kendall-Taylor P, Harris PE. Gs α and Gi2 α mutations in clinically nonfunctioning pituitary tumours. Clin. Endocrinol. (Oxf) 41(6), 815-820 (1994).
34. Williamson EA, Ince PG, Harrison D, Kendall-Taylor P, Harris PE. G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. Eur. J. Clin. Invest. 25(2), 128-131 (1995).
35. Kan B, Esapa C, Sipahi T et al. G protein mutations in pituitary tumors: a study on Turkish patients. Pituitary 6(2), 75-80 (2003).
36. Hibberts NA, Simpson DJ, Bicknell JE et al. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 5(8), 2133-2139 (1999).
37. Zhang X, Horwitz GA, Prezant TR et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 13(1), 156-166 (1999).
38. Hunter JA, Skelly RH, Aylwin SJ et al. The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur. J. Endocrinol. 148(2), 203-211 (2003).
39. Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R. Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol. Rep. 15(6), 1569-1574 (2006).
40. Tfelt-Hansen J, Yano S, Bandyopadhyay S, Carroll R, Brown EM, Chattopadhyay N. Expression of pituitary tumor transforming gene (PTTG) and its binding protein in human astrocytes and astrocytoma cells: function and regulation of PTTG in U87 astrocytoma cells. Endocrinology 145(9), 4222-4231 (2004).
41. Shibata Y, Haruki N, Kuwabara Y et al. Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J. Clin. Oncol. 32(7), 233-237 (2002).
42. Thompson AD, Kakar SS. Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett. 579(14), 3195-3200 (2005).
43. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M. PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 13(1), 80-81 (2004).
44. Rehfeld N, Geddert H, Atamna A et al. The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J. Carcinog. 5(1), 4 (2006).
45. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 55(8), 1613-1616 (1995).
46. Nam DH, Song SY, Park K et al. Clinical significance of molecular genetic changes in sporadic invasive pituitary adenomas. Exp. Mol. Med. 33(3), 111-116 (2001).
47. Bamberger CM, Fehn M, Bamberger AM et al. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur. J. Endocrinol. 140(3), 250-255 (1999).
48. Simpson DJ, Bicknell JE, McNicol AM, Clayton RN, Farrell WE. Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer 24(4), 328-336 (1999).
49. Dahia PL, Aguiar RC, Honegger J et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 16(1), 69-76 (1998).
50. Jaffrain-Rea ML, Ferretti E, Toniato E et al. p16 (INK4a; MTS-1) gene polymorphism and methylation status in human pituitary tumours. Clin. Endocrinol. (Oxf) 51(3), 317-325 (1999).
51. Simpson DJ, McNicol AM, Murray DC et al. Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clin. Cancer Res. 10(5), 1780-1788 (2004).
52. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330(6148), 566-568 (1987).
53. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340(6236), 692-696 (1989).
54. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68, 821-861 (1999).
55. Tian J, Chen J, Bancroft C. Expression of constitutively active Gs α-subunits in GH3 pituitary cells stimulates prolactin promoter activity. J. Biol. Chem. 269(1), 33-36 (1994).
56. Pfaffle RW, Kim C, Blankenstein O, Kentrup H. GH transcription factors. J. Pediatr. Endocrinol. Metab. 12(Suppl. 1), 311-317 (1999).
57. Miyai S, Yoshimura S, Iwasaki Y, Takekoshi S, Lloyd RV, Osamura RY. Induction of GH, PRL, and TSH β mRNA by transfection of Pit-1 in a human pituitary adenoma-derived cell line. Cell Tissue Res. 322(2), 269-277 (2005).
58. Monnier D, Boutillier AL, Giraud P et al. Insulin-like growth factor-I stimulates c-fos and c-jun transcription in PC12 cells. Mol. Cell Endocrinol. 104(2), 139-145 (1994).
59. Crowe DL, Brown TN, Kim R, Smith SM, Lee MK. A c-fos/Estrogen receptor fusion protein promotes cell cycle progression and proliferation of human cancer cell lines. Mol. Cell Biol. Res. Commun. 3(4), 243-248 (2000).
60. Suzuki S, Yamamoto I, Arita J. Mitogen-activated protein kinase-dependent stimulation of proliferation of rat lactotrophs in culture by 3′,5′-cyclic adenosine monophosphate. Endocrinology 140(6), 2850-2858 (1999).
61. Spada A, Arosio M, Bochicchio D et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J. Clin. Endocrinol. Metab. 71(6), 1421-1426 (1990).
62. Landis CA, Harsh G, Lyons J, Davis RL, McCormick F, Bourne HR. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J. Clin. Endocrinol. Metab. 71(6), 1416-1420 (1990).
63. Farrell WE, Clayton RN. Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol. 21(3), 174-198 (2000).
64. Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M, Fahlbusch R. Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 33(2), 198-203; discussion 203 (1993).
65. Yang I, Park S, Ryu M et al. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur. J. Endocrinol. 134(6), 720-726 (1996).
66. Tordjman K, Stern N, Ouaknine G et al. Activating mutations of the Gs α-gene in nonfunctioning pituitary tumors. J. Clin. Endocrinol. Metab. 77(3), 765-769 (1993).
67. Stratakis CA, Matyakhina L, Courkoutsakis N et al. Pathology and molecular genetics of the pituitary gland in patients with the 'complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas' (Carney complex). Front Horm. Res. 32, 253-264 (2004).
68. Raff SB, Carney JA, Krugman D, Doppman JL, Stratakis CA. Prolactin secretion abnormalities in patients with the "syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). J. Pediatr. Endocrinol. Metab. 13(4), 373-379 (2000).
69. Kaltsas GA, Kola B, Borboli N et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin. Endocrinol. (Oxf), 57(4), 443-448 (2002).
70. Sandrini F, Kirschner LS, Bei T et al. PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. J. Med. Genet. 39(12), e78 (2002).
71. Yamasaki H, Mizusawa N, Nagahiro S et al. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24. Clin. Endocrinol. (Oxf), 58(4), 464-470 (2003).
72. Kovacs K, Horvath E, Vidal S. Classification of pituitary adenomas. J. Neurooncol. 54(2), 121-127 (2001).
73. Senovilla L, Nunez L, de Campos JM et al. Multifunctional cells in human pituitary adenomas: implications for paradoxical secretion and tumorigenesis. J. Clin. Endocrinol. Metab. 89(9), 4545-4552 (2004).
74. Ezzat S, Asa SL, Couldwell WT et al. The prevalence of pituitary adenomas: a systematic review. Cancer 101(3), 613-619 (2004).
75. Villalobos C, Nunez L, Garcia-Sancho J. Phenotypic characterization of multifunctional somatotropes, mammotropes and gonadotropes of the mouse anterior pituitary. Pflugers Arch. 449(3), 257-264 (2004).
76. Villalobos C, Nunez L, Frawley LS, Garcia-Sancho J, Sanchez A. Multi-responsiveness of single anterior pituitary cells to hypothalamic-releasing hormones: a cellular basis for paradoxical secretion. Proc. Natl Acad. Sci. USA 94(25), 14132-14137 (1997).
77. Nunez L, Villalobos C, Senovilla L, Garcia-Sancho J. Multifunctional cells of mouse anterior pituitary reveal a striking sexual dimorphism. J. Physiol. 549(Pt 3), 835-843 (2003).
78. Kasahara K, Tasaka K, Masumoto N et al. Characterization of rat pituitary cells by their responses to hypothalamic releasing hormones. Biochem. Biophys. Res. Commun. 199(3), 1436-1441 (1994).
79. Childs GV. Development of gonadotropes may involve cyclic transdifferentiation of growth hormone cells. Arch. Physiol. Biochem. 110(1-2), 42-49 (2002).
80. Vidal S, Horvath E, Kovacs K, Lloyd RV, Smyth HS. Reversible transdifferentiation: interconversion of somatotrophs and lactotrophs in pituitary hyperplasia. Mod. Pathol. 14(1), 20-28 (2001).
81. Vidal S, Horvath E, Kovacs K, Cohen SM, Lloyd RV, Scheithauer BW. Transdifferentiation of somatotrophs to thyrotrophs in the pituitary of patients with protracted primary hypothyroidism. Virchows Arch. 436(1), 43-51 (2000).
82. De Marinis L, Mancini A, Zuppi P, Anile C, Maira G. Paradoxical growth hormone response to thyrotropin-releasing hormone in acromegaly. Clinical correlations and prognostic value. Acta. Endocrinol. (Copenh) 122(4), 443-449 (1990).
83. Tabarin A, Corcuff JB, Rashedi M et al. Multihormonal response to corticotropin-releasing hormone in inferior petrosal sinus blood of one patient with Cushing's disease: comparison with in vitro secretion of the tumoral corticotropes. Acta. Endocrinol. (Copenh) 127(3), 284-288 (1992).
84. Losa M, Schopohl J, Muller OA, von Werder K. Growth hormone releasing factor induces prolactin secretion in acromegalic patients but not in normal subjects. Acta Endocrinol (Copenh) 109(4), 467-473 (1985).
85. Cordido F, Peino R, Martinez-Ramonde T. Persistent GHRH-induced PRL secretion in Cushing's syndrome, obesity and exogenous hypercortisolism. Rev. Esp. Fisiol. 50(3), 139-143 (1994).
86. de la Torre NG, Wass JA, Turner HE. Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas. Front Horm. Res. 32, 133-145 (2004).
87. Yamada S, Takada K. Angiogenesis in pituitary adenomas. Microsc. Res. Tech. 60(2), 236-243 (2003).
88. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA. Angiogenesis in pituitary adenomas and the normal pituitary gland. J. Clin. Endocrinol. Metab. 85(3), 1159-1162 (2000).
89. Viacava P, Gasperi M, Acerbi G et al. Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J. Endocrinol. Invest. 26(1), 23-28 (2003).
90. Jugenburg M, Kovacs K, Stefaneanu L, Scheithauer BW. Vasculature in Nontumorous Hypophyses, Pituitary Adenomas, and Carcinomas: A Quantitative Morphologic Study. Endocr. Pathol. 6(2), 115-124 (1995).
91. Vidal S, Scheithauer BW, Kovacs K. Vascularity in Nontumorous Human Pituitaries and Incidental Microadenomas: A Morphometric Study. Endocr. Pathol. 11(3), 215-227 (2000).
92. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J. Endocrinol. 165(2), 475-481 (2000).
93. Horiguchi H, Jin L, Ruebel KH, Scheithauer BW, Lloyd RV. Regulation of VEGF-A, VEGFR-I, thrombospondin-1, -2, and -3 expression in a human pituitary cell line (HP75) by TGFbeta1, bFGF, and EGF. Endocrine 24(2), 141-146 (2004).
94. Komorowski J, Jankewicz J, Stepien H. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours. Cytobios 101(398), 151-159 (2000).
95. Niveiro M, Aranda FI, Peiro G, Alenda C, Pico A. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum. Pathol. 36(10), 1090-1095 (2005).
96. Schussheim DH, Skarulis MC, Agarwal SK et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol. Metab. 12(4), 173-178 (2001).
97. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276(5311), 404-407 (1997).
98. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68(4), 820-823 (1971).
99. Theodoropoulou M, Cavallari I, Barzon L et al. Differential expression of menin in sporadic pituitary adenomas. Endocr. Relat. Cancer 11(2), 333-344 (2004).
100. Gallo A, Cuozzo C, Esposito I et al. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Oncogene 21(42), 6434-6445 (2002).
101. Heppner C, Bilimoria KY, Agarwal SK et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 20(36), 4917-4925 (2001).
102. Agarwal SK, Guru SC, Heppner C et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96(1), 143-152 (1999).
103. Ikeo Y, Sakurai A, Suzuki R et al. Proliferation-associated expression of the MEN1 gene as revealed by in situ hybridization: possible role of the menin as a negative regulator of cell proliferation under DNA damage. Lab. Invest. 80(6), 797-804 (2000).
104. Guru SC, Goldsmith PK, Burns AL et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl Acad Sci. USA 95(4), 1630-1634 (1998).
105. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann. Intern. Med. 129(6), 484-494 (1998).
106. Pannett AA, Thakker RV. Multiple endocrine neoplasia type 1. Endocr. Relat. Cancer 6(4), 449-473 (1999).
107. Evans CO, Brown MR, Parks JS, Oyesiku NM. Screening for MEN1 tumor suppressor gene mutations in sporadic pituitary tumors. J. Endocrinol. Invest. 23(5), 304-309 (2000).
108. Wenbin C, Asai A, Teramoto A, Sanno N, Kirino T. Mutations of the MEN1 tumor suppressor gene in sporadic pituitary tumors. Cancer Lett. 142(1), 43-47 (1999).
109. Zhuang Z, Ezzat SZ, Vortmeyer AO et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res, 57(24), 5446-5451 (1997).
110. Marx SJ, Nieman LK. Aggressive pituitary tumors in MEN1: do they refute the two-hit model of tumorigenesis? J. Clin. Endocrinol. Metab. 87(2), 453-456 (2002).
111. Weil RJ, Vortmeyer AO, Huang S et al. 11q13 allelic loss in pituitary tumors in patients with multiple endocrine neoplasia syndrome type 1. Clin. Cancer Res. 4(7), 1673-1678 (1998).
112. Verges B, Boureille F, Goudet P et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab. 87(2), 457-465 (2002).
113. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 64(4), 270-283 (1985).
114. Carney JA, Hruska LS, Beauchamp GD, Gordon H. Dominant inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Mayo Clin. Proc. 61(3), 165-172 (1986).
115. Atherton DJ, Pitcher DW, Wells RS, MacDonald DM. A syndrome of various cutaneous pigmented lesions, myxoid neurofibromata and atrial myxoma: the NAME syndrome. Br. J. Dermatol. 103(4), 421-429 (1980).
116. Bossis I, Voutetakis A, Bei T, Sandrini F, Griffin KJ, Stratakis CA. Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr. Relat. Cancer 11(2), 265-280 (2004).
117. Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis CA. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). J. Clin. Endocrinol. Metab. 85(10), 3860-3865 (2000).
118. Watson JC, Stratakis CA, Bryant-Greenwood PK et al. Neurosurgical implications of Carney complex. J. Neurosurg. 92(3), 413-418 (2000).
119. McCune DJ. Osteitis fibrosa cystica: the case of nine year old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am. J. Dis. Child 52, 743-747 (1936).
120. Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females: reports of five cases. N. Engl. J. Med. 216, 727-746 (1937).
121. Chanson P, Dib A, Visot A, Derome PJ. McCune-Albright syndrome and acromegaly: clinical studies and response to treatment in five cases. Eur. J. Endocrinol. 131, 229-234 (1994).
122. Premawardhana LDKE, Vora JP, Mills R, Scanlon MF. Acromegaly and its treatment in the McCune-Albright syndrome. Clin. Endocrinol. 36, 605-608 (1992).
123. Obuobie K, Mullik V, Jones C et al. McCune-Albright syndrome: growth hormone dynamics in pregnancy. J. Clin. Endocrinol. Metab. 86, 2456-2458 (2001).
124. Akintoye SO, Chebli C, Booher S et al. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 87, 5104-5112 (2002).
125. Ihara C, Shimatsu A, Murabe H, Kataoka K, Kondo C, Nakao K. Growth hormone secreting pituitary adenoma associated with multiple bone cysts, skin pigmenterion and aortitis syndrome. J. Endocrinol. Invest. 19, 753-757 (1996).
126. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N. Engl. J. Med. 325, 1688-1695 (1991).
127. Jorge BH, Agarwal SK, Lando VS et al. Study of the multiple endocrine neoplasia type 1, growth hormone-releasing hormone receptor, Gs α, and Gi2 α genes in isolated familial acromegaly. J. Clin. Endocrinol. Metab. 86(2), 542-544 (2001).
128. Verloes A, Stevenaert A, Teh BT, Petrossians P, Beckers A. Familial acromegaly: case report and review of the literature. Pituitary 1(3-4), 273-277 (1999).
129. Yamada S, Yoshimoto K, Sano T et al. Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 82(1), 239-242 (1997).
130. Gadelha MR, Prezant TR, Une KN et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J. Clin. Endocrinol. Metab. 84(1), 249-256 (1999).
131. Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman RD, Frohman LA. Isolated familial somatotropinomas. establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J. Clin. Endocrinol. Metab. 85(2), 707-714 (2000).
132. Seilicovich A, Pisera D, Sciascia SA et al. Gene therapy for pituitary tumors. Curr. Gene Ther. 5(6), 559-572 (2005).
133. Lee EJ, Jameson JL. Gene therapy of pituitary diseases. J. Endocrinol. 185(3), 353-362 (2005).
134. Lee EJ, Martinson F, Kotlar T, Thimmapaya B, Jameson JL. Adenovirus-mediated targeted expression of toxic genes to adrenocorticotropin-producing pituitary tumors using the proopiomelanocortin promoter. J. Clin. Endocrinol. Metab. 86(7), 3400-3409 (2001).
135. Lee EJ, Anderson LM, Thimmapaya B, Jameson JL. Targeted expression of toxic genes directed by pituitary hormone promoters: a potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J. Clin. Endocrinol. Metab. 84(2), 786-794 (1999).
136. Riley DJ, Nikitin AY, Lee WH. Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/- mice. Nat. Med. 2(12), 1316-1321 (1996).
137. Daniely M, Aviram A, Adams EF et al. Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. J. Clin. Endocrinol. Metab. 83(5), 1801-1805 (1998).
138. Hui AB, Pang JC, Ko CW, Ng HK. Detection of chromosomal imbalances in growth hormone-secreting pituitary tumors by comparative genomic hybridization. Hum. Pathol. 30(9), 1019-1023 (1999).
139. Caccavelli L, Feron F, Morange I et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60(3), 314-322 (1994).
140. Roux F, Durieu-Trautmann O, Chaverot N et al. Regulation of γ-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J. Cell Physiol. 159(1), 101-113 (1994).
141. Honda S, Tanaka-Kosugi C, Yamada S et al. Human pituitary adenomas infrequently contain inactivation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene. Endocr. J. 50(3), 309-318 (2003).
142. Capella C, Riva C, Leutner M, La Rosa S. Pituitary lesions in multiple endocrine neoplasia syndrome (MENS) type 1. Pathol. Res. Pract, 191(4), 345-347 (1995).